Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAXIPEM: Axitinib +/- Pembrolizumab in PRCC
NCT05096390Phase 2Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in papillary renal cell carcinoma (PRCC), sponsored by Centre Léon Bérard. Started Jun 2022; status: recruiting.
02
Drugs
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT05096390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05096390.